Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.48 |
| ▸ | ACVR2A | P27037 | 3/20 | 0.41 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29927552 | 1.00 | NLRP3 (0.48) | NLRP3ACVR2ATGFBR2AAK1DYRK1A | |
| SCHEMBL20742969 | 0.88 | MAPK14 (0.42) | NLRP3ACVR2ATGFBR2MAPK13MAPK12 | |
| SCHEMBL20744375 | 0.88 | NLRP3 (0.41) | NLRP3ACVR2ATGFBR2AAK1MAPK13 | |
| SCHEMBL30684077 | 0.88 | NLRP3 (0.41) | NLRP3ACVR2ATGFBR2AAK1MAPK13 | |
| SCHEMBL30684129 | 0.88 | MAPK14 (0.42) | NLRP3ACVR2ATGFBR2MAPK13MAPK12 | |
| SCHEMBL22773957 | 0.87 | NLRP3 (0.48) | NLRP3ACVR2ATGFBR2AAK1DYRK1A | |
| SCHEMBL29467111 | 0.87 | NLRP3 (0.48) | NLRP3ACVR2ATGFBR2AAK1DYRK1A | |
| SCHEMBL22827688 | 0.86 | ACVR2A (0.43) | NLRP3ACVR2ATGFBR2AAK1DYRK1A | |
| SCHEMBL23385498 | 0.86 | NLRP3 (0.46) | NLRP3ACVR2ATGFBR2AAK1DYRK1A | |
| SCHEMBL30642351 | 0.86 | NLRP3 (0.46) | NLRP3ACVR2ATGFBR2AAK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2025-04-10 | — | — | US | disclosed |
| US-12168653-B2 | Sulfonamide derivates as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-12-17 | — | — | US | disclosed |
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-07-09 | — | — | US | disclosed |
| US-12012392-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-06-18 | — | — | US | disclosed |
| US-11981667-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-05-14 | — | — | US | disclosed |
| US-11926600-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-03-12 | — | — | US | disclosed |
| US-11884645-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-01-30 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| WO-2019034693-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034692-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034693-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034690-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034697-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034686-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019008029-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
| WO-2019008029-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
| WO-2019008025-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
| WO-2019008025-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | NLRP3 1/4885ACVR2A 3773/4885TGFBR2 2327/4885 |
| US-11773058-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, NLRP1 | NLRP3 1/4885ACVR2A 3184/4885TGFBR2 1882/4885 |
| US-11884645-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, ABCC5 | NLRP3 1/4885ACVR2A 3657/4885TGFBR2 2291/4885 |
| US-11981667-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, PYCARD | NLRP3 1/4885ACVR2A 3802/4885TGFBR2 3152/4885 |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | NLRP3 1/4885ACVR2A 3804/4885TGFBR2 3161/4885 |
| US-11926600-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | NLRP3 1/4885ACVR2A 4448/4885TGFBR2 2559/4885 |
| US-12168653-B2 | Sulfonamide derivates as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | NLRP3 1/4885ACVR2A 4303/4885TGFBR2 1529/4885 |
| US-12012392-B2 | Sulfonamide carboxamide compounds | NLRP3, PYCARD, NOD1 | NLRP3 1/4885ACVR2A 4403/4885TGFBR2 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.